Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation

European Radiology

Volumn 22, Issue 9, 2012, Pages 2007-2012

  Bannas, Peter ^a   Hentschel, Hannah B ^a   Bley, Thorsten A ^a   Treszl, András ^a   Eulenburg, Christine ^a   Derlin, Thorsten ^a   Yamamura, Jin ^a   Adam, Gerhard ^a   Stübig, Thomas ^a   Kröger, Nicolaus ^a   Weber, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

MRI; Multiple myeloma; Stem cell transplantation; Therapy monitoring; Whole body magnetic resonance imaging

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LABORATORY TEST; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; WHOLE BODY MRI;

ADULT; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84864694810     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2445-y     Document Type: Article

References (25)

1. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336:1657-1664
2. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046-1060
3. Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875-887
4. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
5. Bensinger WI (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-448
6. Lokhorst H, Einsele H, Vesole D et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 28:4521-4530
7. Kroger N (2007) Mini-Midi-Maxi? How to harness the graftversus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 21:1851-1858
8. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502
9. Barlogie B, Tricot GJ, van Rhee F et al (2006) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135:158-164
10. Harousseau JL, Dreyling M (2009) Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:97-99
11. Kroger N, Bacher U, Bader P et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16:1187-1211
12. Rajkumar SV, Harousseau JL, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691-4695
13. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473
14. Dimopoulos M, Terpos E, Comenzo RL et al (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 23:1545-1556
15. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M (2007) Guidelines for the use of imaging in the management of myeloma. Br J Haematol 137:49-63
16. Derlin T, Weber C, Habermann CR et al (18)F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1993-8
17. Fonti R, Salvatore B, Quarantelli M et al (2008) 18 F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 49:195-200
18. Shortt CP, Carty F, Murray JG. The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma. Semin Musculoskelet Radiol 14:37-46
19. Durie BG (2006) The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. Eur J Cancer 42:1539-1543
20. Lecouvet FE, Dechambre S, Malghem J, Ferrant A, Vande Berg BC, Maldague B (2001) Bone marrow transplantation in patients with multiple myeloma: Prognostic significance of MR imaging. AJR Am J Roentgenol 176:91-96
21. Lin C, Luciani A, Belhadj K et al. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 254:521-531
22. Blade J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123
23. Kramer MS, Feinstein AR (1981) Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 29:111-123
24. Bauerle T, Hillengass J, Fechtner K et al (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: Importance of whole-body versus spinal MR imaging. Radiology 252:477-485
25. Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: Preliminary results. AJR Am J Roentgenol 196:W790-795